These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 29050675

  • 1. Comparison of serum acetyl hydrolase (PAF-AH) and paraoxonase 1 (PON1) values between prostate cancer patients and a control group.
    Benli E, Bayrak A, Cirakoglu A, Bayrak T, Noyan T.
    Kaohsiung J Med Sci; 2017 Nov; 33(11):572-577. PubMed ID: 29050675
    [Abstract] [Full Text] [Related]

  • 2. Higher Levels of Oxidized Low Density Lipoproteins in Alzheimer's Disease Patients: Roles for Platelet Activating Factor Acetyl Hydrolase and Paraoxonase-1.
    Bacchetti T, Vignini A, Giulietti A, Nanetti L, Provinciali L, Luzzi S, Mazzanti L, Ferretti G.
    J Alzheimers Dis; 2015 Nov; 46(1):179-86. PubMed ID: 25720407
    [Abstract] [Full Text] [Related]

  • 3. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis.
    Liberopoulos EN, Papavasiliou E, Miltiadous GA, Cariolou M, Siamopoulos KC, Tselepis AD, Elisaf MS.
    Perit Dial Int; 2004 Nov; 24(6):580-9. PubMed ID: 15559488
    [Abstract] [Full Text] [Related]

  • 4. The PON1 M55L gene polymorphism is associated with reduced HDL-associated PAF-AH activity.
    Kakafika AI, Xenofontos S, Tsimihodimos V, Tambaki AP, Lourida ES, Kalaitzidis R, Cariolou MA, Elisaf M, Tselepis AD.
    J Lipid Res; 2003 Oct; 44(10):1919-26. PubMed ID: 12867538
    [Abstract] [Full Text] [Related]

  • 5. The platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome.
    Carlioglu A, Kaygusuz I, Karakurt F, Gumus II, Uysal A, Kasapoglu B, Armutcu F, Uysal S, Keskin EA, Koca C.
    Arch Gynecol Obstet; 2014 Nov; 290(5):929-35. PubMed ID: 24840107
    [Abstract] [Full Text] [Related]

  • 6. Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia.
    Kiortsis DN, Tsouli S, Lourida ES, Xydis V, Argyropoulou MI, Elisaf M, Tselepis AD.
    Angiology; 2005 Nov; 56(4):451-8. PubMed ID: 16079929
    [Abstract] [Full Text] [Related]

  • 7. Serum paraoxonase 1 and 3 activities in benign and malignant diseases of the prostate and changes in levels following robotic-assisted laparoscopic radical prostatectomy.
    Bedir F, Kocatürk H, Altay MS, Şebin E, Bedir B.
    Turk J Med Sci; 2020 Dec 17; 50(8):1872-1878. PubMed ID: 32549522
    [Abstract] [Full Text] [Related]

  • 8. Paraoxonase lactonase activity (PON-HTLase), asymmetric dimethylarginine (ADMA) and platelet activating factor-acetylhydrolase (PAF-AH) activity in non-obese women with PCOS.
    Bayrak T, Dursun P, Bayrak A, Gültekin M, Kolusarı A, Cakır E, Ozyurt M, Zeyneloğlu HB.
    Gynecol Endocrinol; 2012 Nov 17; 28(11):874-8. PubMed ID: 22621680
    [Abstract] [Full Text] [Related]

  • 9. The paraoxonase 1 (PON1), platelet-activating factor acetylohydrolase (PAF-AH) and dimethylarginine dimethylaminohydrolase (DDAH) activity in the metformin treated normal and diabetic rats.
    Wójcicka G, Jamroz-Wiśniewska A, Czechowska G, Korolczuk A, Marciniak S, Bełtowski J.
    Eur J Pharmacol; 2016 Oct 15; 789():187-194. PubMed ID: 27450486
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome.
    Rizos E, Tambaki AP, Gazi I, Tselepis AD, Elisaf M.
    Prostaglandins Leukot Essent Fatty Acids; 2005 Mar 15; 72(3):203-9. PubMed ID: 15664305
    [Abstract] [Full Text] [Related]

  • 13. Paraoxonase and platelet-activating factor acetylhydrolase activities in lipoproteins of beta-thalassemia/hemoglobin E patients.
    Phumala Morales N, Cherlermchoung C, Fucharoen S, Chantharaksri U.
    Clin Chem Lab Med; 2007 Mar 15; 45(7):884-9. PubMed ID: 17617032
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The differentiating effect of glimepiride and glibenclamide on paraoxonase 1 and platelet-activating factor acetylohydrolase activity.
    Wójcicka G, Jamroz-Wiśniewska A, Marciniak A, Łowicka E, Bełtowski J.
    Life Sci; 2010 Jul 17; 87(3-4):126-32. PubMed ID: 20638992
    [Abstract] [Full Text] [Related]

  • 16. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.
    Ferro M, Bruzzese D, Perdonà S, Marino A, Mazzarella C, Perruolo G, D'Esposito V, Cosimato V, Buonerba C, Di Lorenzo G, Musi G, De Cobelli O, Chun FK, Terracciano D.
    PLoS One; 2013 Jul 17; 8(7):e67687. PubMed ID: 23861782
    [Abstract] [Full Text] [Related]

  • 17. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.
    Tsimihodimos V, Karabina SA, Tambaki AP, Bairaktari E, Goudevenos JA, Chapman MJ, Elisaf M, Tselepis AD.
    Arterioscler Thromb Vasc Biol; 2002 Feb 01; 22(2):306-11. PubMed ID: 11834533
    [Abstract] [Full Text] [Related]

  • 18. Phospholipase action of platelet-activating factor acetylhydrolase, but not paraoxonase-1, on long fatty acyl chain phospholipid hydroperoxides.
    Kriska T, Marathe GK, Schmidt JC, McIntyre TM, Girotti AW.
    J Biol Chem; 2007 Jan 05; 282(1):100-8. PubMed ID: 17090529
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.